Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide.
Scholar Rock Holding (SRRK) updated investors after shifting apitegromab's commercial fill finish work away from Catalent Indiana following FDA inspection issues, while confirming that the FDA is continuing its review, a revised European filing is underway, and a Japanese submission is planned without new trials.
See our latest analysis for Scholar Rock Holding.
Investor attention around Scholar Rock Holding has coincided with strong recent momentum, with a 7 day share price return of 7.58%, a 30 day share price return of 16.98% and a 1 year total shareholder return of 59.2%. Over 3 years, the total shareholder return is reported to be more than 8 times the original value.
If you are looking beyond Scholar Rock Holding for other opportunities in high growth health related technologies, this could be a good moment to check out 41 healthcare AI stocks
Scholar Rock Holding now appears to be a company with a lead SMA asset progressing through regulators and a stock that has already delivered very strong multi year gains. The next step is to evaluate how that business story aligns with today's valuation.
Most Popular Narrative: 5% Undervalued
At a last close of $56.50 versus a narrative fair value of $59.31, Scholar Rock Holding is framed as modestly undervalued, with that gap hinging on a single asset moving from development stage to commercial stage.
Scholar Rock Holding focuses on developing muscle-targeted therapies for rare and severe neuromuscular diseases, led by its apitegromab program for spinal muscular atrophy and a broader anti myostatin pipeline.
Want to see what underpins that premium setup for Scholar Rock Holding? The narrative leans heavily on revenue scaling, richer margins and a future earnings multiple.
Result: Fair Value of $59.31 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Scholar Rock Holding's story still hinges on apitegromab's regulatory timing and commercial uptake, so any approval delays or slower than expected adoption could quickly challenge that 5% undervalued setup.
Find out about the key risks to this Scholar Rock Holding narrative.
Another View on Scholar Rock Holding's Valuation
The analyst narrative frames Scholar Rock Holding as modestly undervalued using future earnings and a very high implied P/E, yet the current P/B of 27.1x is much higher than both peers at 12.5x and the US Biotechs industry at 2.5x. That gap suggests a lot is already priced in, so which signal do you trust more?
For a closer look at what the numbers say about this pricing gap, including where the ratio could drift over time, See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With Scholar Rock Holding attracting both optimism and caution, this is a moment to move quickly, review the full picture and decide where you stand. To weigh both sides of the story in one place, start with 2 key rewards and 3 important warning signs
Looking for more investment ideas beyond Scholar Rock Holding?
If you want a broader watchlist alongside Scholar Rock Holding, do not wait around. Fresh opportunities can move quickly, so give yourself more options now.
-
Target potential value by checking companies that look mispriced on fundamentals with the 48 high quality undervalued stocks
-
Strengthen downside protection by reviewing companies highlighted in the 78 resilient stocks with low risk scores
-
Hunt for lesser known opportunities that still show solid fundamentals using the screener containing 19 high quality undiscovered gems
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include SRRK .
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
